Christopher Paul Cannon, M.D.
Co-Author
This page shows the publications co-authored by Christopher Cannon and Deepak Bhatt.
Connection Strength
10.106
-
Clinical trials update from the annual scientific session of the American College of Cardiology 2006. Am J Cardiol. 2006 Dec 18; 98(12A):36Q-41Q.
Score: 0.341
-
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Dec; 3(5):619-634.
Score: 0.243
-
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EuroIntervention. 2021 Aug 27; 17(6):474-480.
Score: 0.239
-
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021 Jun 16.
Score: 0.236
-
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). Clin Cardiol. 2021 Jul; 44(7):1002-1010.
Score: 0.235
-
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. Eur Heart J Cardiovasc Pharmacother. 2020 Dec 01.
Score: 0.227
-
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 01 14; 384(2):129-139.
Score: 0.226
-
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 01 14; 384(2):117-128.
Score: 0.226
-
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. Circ Cardiovasc Interv. 2020 04; 13(4):e008349.
Score: 0.217
-
Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. Am J Cardiol. 2020 05 15; 125(10):1577-1581.
Score: 0.216
-
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020 01 21; 75(2):238-240.
Score: 0.214
-
Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range. J Am Coll Cardiol. 2019 11 12; 74(19):2431-2433.
Score: 0.211
-
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.
Score: 0.210
-
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019 05 14; 40(19):1553-1562.
Score: 0.204
-
Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. J Am Coll Cardiol. 2019 04 02; 73(12):1596-1598.
Score: 0.202
-
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. Am Heart J. 2019 06; 212:13-22.
Score: 0.201
-
Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Eur Heart J. 2019 01 07; 40(2):218-219.
Score: 0.199
-
Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol. 2018 12 25; 72(25):3370-3372.
Score: 0.198
-
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018 05 14; 39(19):1726-1735a.
Score: 0.190
-
Quality Improvement in Management of Acute Coronary Syndrome: Continuing Medical Education and Peer Coaching Improve Antiplatelet Medication Adherence and Reduce Hospital Readmissions. Crit Pathw Cardiol. 2017 09; 16(3):96-101.
Score: 0.181
-
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 10 19; 377(16):1513-1524.
Score: 0.181
-
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol. 2016 Oct; 39(10):555-564.
Score: 0.169
-
Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines--Coronary Artery Disease Data Set). Am J Cardiol. 2016 Jan 15; 117(2):201-5.
Score: 0.160
-
The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Aliment Pharmacol Ther. 2015 Aug; 42(3):365-74.
Score: 0.155
-
Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply. Clin Cardiol. 2014 May; 37(5):323.
Score: 0.142
-
Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. Circ Cardiovasc Qual Outcomes. 2014 Mar; 7(2):227-35.
Score: 0.142
-
Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists. Clin Cardiol. 2014 Feb; 37(2):103-7.
Score: 0.141
-
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23; 310(16):1711-20.
Score: 0.139
-
Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. Clin Cardiol. 2013 Dec; 36(12):749-56.
Score: 0.138
-
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013 Jan 08; 61(1):35-40.
Score: 0.130
-
Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines. Clin Cardiol. 2012; 35(7):396-403.
Score: 0.122
-
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11; 363(20):1909-17.
Score: 0.112
-
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Feb 15; 105(4):445-52.
Score: 0.107
-
Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation. 2009 Aug 18; 120(7):560-7.
Score: 0.103
-
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202.
Score: 0.101
-
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.
Score: 0.096
-
An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5.
Score: 0.089
-
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104.
Score: 0.074
-
A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention. 2022 Feb 02.
Score: 0.062
-
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
Score: 0.059
-
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol. 2021 08 01; 6(8):880-888.
Score: 0.059
-
Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur J Prev Cardiol. 2021 07 23; 28(8):e12-e14.
Score: 0.059
-
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Ann Intern Med. 2021 08; 174(8):1065-1072.
Score: 0.059
-
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC Cardiovasc Interv. 2021 04 12; 14(7):768-780.
Score: 0.058
-
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.
Score: 0.058
-
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. Circulation. 2021 02 09; 143(6):583-596.
Score: 0.057
-
Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021 01 05; 325(1):39-49.
Score: 0.057
-
2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 02 09; 77(5):629-658.
Score: 0.057
-
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
Score: 0.057
-
Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. Clin Cardiol. 2020 Nov; 43(11):1209-1215.
Score: 0.056
-
Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thromb Res. 2020 11; 195:128-135.
Score: 0.055
-
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs. 2020 Jul; 80(10):995-1005.
Score: 0.055
-
Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur J Prev Cardiol. 2020 Jun 23.
Score: 0.055
-
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. Am J Med. 2020 11; 133(11):1302-1312.
Score: 0.055
-
Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol. 2020 05 01; 5(5):582-589.
Score: 0.054
-
No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC Cardiovasc Interv. 2020 04 27; 13(8):1012-1014.
Score: 0.054
-
Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. JAMA Netw Open. 2020 04 01; 3(4):e203032.
Score: 0.054
-
Reply: Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes. JACC Cardiovasc Interv. 2020 03 09; 13(5):658-659.
Score: 0.054
-
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis. JACC Cardiovasc Interv. 2019 12 09; 12(23):2331-2341.
Score: 0.053
-
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. JACC Cardiovasc Interv. 2019 12 09; 12(23):2346-2355.
Score: 0.053
-
Comparison of the Effect of Age (< 75 Versus = 75) on the Efficacy and Safety of Dual Therapy (Dabigatran?+?Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin?+?Aspirin?+?Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). Am J Cardiol. 2020 03 01; 125(5):735-743.
Score: 0.053
-
Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care. 2020 08; 43(8):1843-1850.
Score: 0.052
-
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. JACC Cardiovasc Interv. 2019 08 26; 12(16):1553-1561.
Score: 0.052
-
Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol. 2019 08 01; 4(8):747-755.
Score: 0.052
-
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 07 09; 74(1):83-99.
Score: 0.051
-
Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 08 13; 140(7):618-620.
Score: 0.051
-
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. J Am Coll Cardiol. 2019 05 21; 73(19):2439-2450.
Score: 0.051
-
Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
Score: 0.049
-
WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. Am J Cardiol. 2018 Aug 16.
Score: 0.048
-
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. Circulation. 2018 07 31; 138(5):527-536.
Score: 0.048
-
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. Am Heart J. 2018 08; 202:97-103.
Score: 0.048
-
Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clin Cardiol. 2018 Jun; 41(6):758-768.
Score: 0.048
-
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018 01 23; 71(3):292-302.
Score: 0.046
-
Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clin Cardiol. 2017 Oct; 40(10):932-939.
Score: 0.045
-
Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. Am Heart J. 2017 May; 187:78-87.
Score: 0.044
-
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016 11; 9(11).
Score: 0.043
-
Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. J Am Coll Cardiol. 2016 08 30; 68(9):981-2.
Score: 0.042
-
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med. 2016 Sep; 129(9):1002-5.
Score: 0.041
-
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12; 67(14):1661-71.
Score: 0.041
-
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. Am J Med. 2015 Apr; 128(4):426.e1-9.
Score: 0.037
-
Targeted versus standard feedback: results from a randomized quality improvement trial. Am Heart J. 2015 Jan; 169(1):132-41.e2.
Score: 0.037
-
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014 Nov 01; 35(41):2864-72.
Score: 0.036
-
Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD. Clin Cardiol. 2014 May; 37(5):285-92.
Score: 0.035
-
NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014 Jan; 127(1):53-60.e1.
Score: 0.035
-
Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. Circulation. 2013 Nov 26; 128(22):2447-60.
Score: 0.035
-
Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol. 2013 Dec; 36(12):721-7.
Score: 0.035
-
Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013 Aug; 126(8):693-700.e1.
Score: 0.034
-
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14.
Score: 0.032
-
ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 03; 308(13):1340-9.
Score: 0.032
-
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):654-61.
Score: 0.032
-
Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program. J Am Heart Assoc. 2012 Aug; 1(4):e001206.
Score: 0.032
-
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013 Jan; 126(1):74.e1-9.
Score: 0.032
-
Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol. 2012 Sep; 35(9):541-7.
Score: 0.032
-
Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. Clin Cardiol. 2012 Oct; 35(10):632-40.
Score: 0.032
-
Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. Am J Med. 2012 Oct; 125(10):1000-9.
Score: 0.032
-
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 03; 126(1):65-75.
Score: 0.031
-
Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. Circ Cardiovasc Qual Outcomes. 2012 Jan; 5(1):126-33.
Score: 0.031
-
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol. 2011 Oct 18; 58(17):1760-5.
Score: 0.030
-
Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):610-8.
Score: 0.030
-
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011 Oct; 86(10):960-7.
Score: 0.030
-
Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). Am Heart J. 2011 Aug; 162(2):283-290.e2.
Score: 0.030
-
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). Am Heart J. 2011 Feb; 161(2):418-424.e1-3.
Score: 0.029
-
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010 Dec; 160(6):1130-6, 1136.e1-3.
Score: 0.028
-
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol. 2010 Sep; 9(3):116-25.
Score: 0.028
-
Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2010 Sep 14; 122(11):1091-100.
Score: 0.028
-
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J. 2009 Dec; 158(6):1038-45.
Score: 0.026
-
Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA. 2009 Nov 25; 302(20):2207-13.
Score: 0.026
-
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009 Nov 17; 54(21):1935-45.
Score: 0.026
-
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.
Score: 0.026
-
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009 Sep; 8(3):104-11.
Score: 0.026
-
Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. Crit Pathw Cardiol. 2009 Jun; 8(2):91-7.
Score: 0.026
-
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 Apr 02; 299(13):1547-60.
Score: 0.024
-
Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1.
Score: 0.023
-
Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6.
Score: 0.023
-
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20.
Score: 0.023
-
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9.
Score: 0.023
-
Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7.
Score: 0.023
-
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35.
Score: 0.023
-
Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36.
Score: 0.023
-
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007 May 01; 99(9):1212-5.
Score: 0.022
-
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 01; 98(9):1172-6.
Score: 0.021
-
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11.
Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.